Assessing the Burden of Respiratory Syncytial Virus (RSV)
Launched by ABU DHABI HEALTH SERVICES COMPANY · Jun 3, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding Respiratory Syncytial Virus, or RSV, which can cause serious respiratory infections in people of all ages, from babies to older adults. Researchers will look at hospital records from January 2018 to December 2024 to learn more about how common RSV is, who is most likely to get it, and what the long-term effects and costs of RSV infection are. This information will help improve care for patients affected by RSV.
To participate in this study, individuals must have a confirmed diagnosis of RSV and have been admitted to a SEHA hospital or healthcare facility during the study period. Unfortunately, patients with suspected RSV that hasn't been confirmed by a lab test or those without enough information in the hospital records won't be included. While the trial is not yet recruiting participants, it's an important step towards better understanding and managing RSV in the community.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients of all ages with a confirmed diagnosis of RSV infection
- • Patients admitted to a SEHA hospital or healthcare facility between January 2018 and December 2024
- • Patients with documented data in the SEHA electronic medical record (EMR) system
- Exclusion Criteria:
- • Patients with suspected RSV infection that is not laboratory-confirmed
- • Patients without sufficient data in the SEHA EMR system
About Abu Dhabi Health Services Company
Abu Dhabi Health Services Company (SEHA) is a leading healthcare provider in the United Arab Emirates, committed to delivering high-quality medical services and advancing healthcare innovation. As a prominent sponsor of clinical trials, SEHA focuses on enhancing patient care through rigorous research and development initiatives. The organization collaborates with local and international partners to facilitate studies that address critical health challenges, ensuring adherence to the highest ethical and regulatory standards. By fostering an environment of scientific inquiry, SEHA aims to contribute to the global medical community and improve health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Abu Dhabi, , United Arab Emirates
Patients applied
Trial Officials
Salah Eldin Hussein, MD
Study Director
Abu Dhabi Health Services Company-SEHA
Nawal Alkaabi, MD
Principal Investigator
Abu Dhabi Health Services Company-SEHA
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported